AH Bio Fund II, L.P. - 27 Jul 2026 Form 4 Insider Report for Scribe Therapeutics, Inc. (SCTX)

Reporting relationship: 10%+ Owner
Issuer ticker: SCTX
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2026, 19:09:52 UTC
Prior SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: AH Bio Fund II, L.P., By AH Equity Partners Bio II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer

Key filing fact

AH Bio Fund II, L.P. filed Form 4 for Scribe Therapeutics, Inc. (SCTX) on 29 Jul 2026.

Key facts

This page summarizes AH Bio Fund II, L.P.'s Form 4 filing for Scribe Therapeutics, Inc. (SCTX).
5 reported transactions and 12 derivative rows are listed below.
Accepted by SEC: 29 Jul 2026, 19:09.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001725721 Primary reporting owner

AH Bio Fund II, L.P.

Relationship: 10%+ Owner
Address: C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK
Signature: AH Bio Fund II, L.P., By AH Equity Partners Bio II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
Signature date: 29 Jul 2026

CIK 0001725722

AH Equity Partners Bio II, L.L.C.

Relationship: 10%+ Owner
Address: C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK
Signature: AH Equity Partners Bio II, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
Signature date: 29 Jul 2026

CIK 0001799477

AH Bio Fund III, L.P.

Relationship: 10%+ Owner
Address: C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK
Signature: AH Bio Fund III, L.P., By AH Equity Partners Bio III, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
Signature date: 29 Jul 2026

CIK 0001799478

AH Equity Partners Bio III, L.L.C.

Relationship: 10%+ Owner
Address: C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK
Signature: AH Equity Partners Bio III, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
Signature date: 29 Jul 2026

CIK 0001160077

Andreessen Marc L

Relationship: 10%+ Owner
Address: C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK
Signature: /s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen
Signature date: 29 Jul 2026

CIK 0001166586

HOROWITZ BENJAMIN A

Relationship: 10%+ Owner
Address: C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK
Signature: /s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,051,742
Change %
Price
Shares after: 2,051,742
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F1, F2

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,051,742
Change %
Price
Shares after: 2,051,742
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F1, F2

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,051,742
Change %
Price
Shares after: 2,051,742
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F1, F2

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,051,742
Change %
Price
Shares after: 2,051,742
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F1, F2

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,051,742
Change %
Price
Shares after: 2,051,742
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F1, F2

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,051,742
Change %
Price
Shares after: 2,051,742
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F1, F2

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +697,650
Change %
Price
Shares after: 697,650
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +697,650
Change %
Price
Shares after: 697,650
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +697,650
Change %
Price
Shares after: 697,650
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +697,650
Change %
Price
Shares after: 697,650
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +697,650
Change %
Price
Shares after: 697,650
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +697,650
Change %
Price
Shares after: 697,650
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Footnotes: F1, F3, F4

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +333,333
Change %: +16%
Price: $15.00^*
Shares after: 2,385,075
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F2

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +333,333
Change %: +16%
Price: $15.00^*
Shares after: 2,385,075
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F2

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +333,333
Change %: +16%
Price: $15.00^*
Shares after: 2,385,075
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F2

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +333,333
Change %: +16%
Price: $15.00^*
Shares after: 2,385,075
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F2

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +333,333
Change %: +16%
Price: $15.00^*
Shares after: 2,385,075
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F2

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +333,333
Change %: +16%
Price: $15.00^*
Shares after: 2,385,075
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,150,003
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Underlying class: Common Stock
Underlying amount: 2,051,742
Exercise price
Footnotes: F1, F2

SCTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,150,003
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Underlying class: Common Stock
Underlying amount: 2,051,742
Exercise price
Footnotes: F1, F2

SCTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,150,003
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Underlying class: Common Stock
Underlying amount: 2,051,742
Exercise price
Footnotes: F1, F2

SCTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,150,003
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Underlying class: Common Stock
Underlying amount: 2,051,742
Exercise price
Footnotes: F1, F2

SCTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,150,003
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Underlying class: Common Stock
Underlying amount: 2,051,742
Exercise price
Footnotes: F1, F2

SCTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,150,003
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund II, L.P.
Underlying class: Common Stock
Underlying amount: 2,051,742
Exercise price
Footnotes: F1, F2

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,131,344
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Underlying class: Common Stock
Underlying amount: 697,650
Exercise price
Footnotes: F1, F3, F4

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,131,344
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Underlying class: Common Stock
Underlying amount: 697,650
Exercise price
Footnotes: F1, F3, F4

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,131,344
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Underlying class: Common Stock
Underlying amount: 697,650
Exercise price
Footnotes: F1, F3, F4

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,131,344
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Underlying class: Common Stock
Underlying amount: 697,650
Exercise price
Footnotes: F1, F3, F4

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,131,344
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Underlying class: Common Stock
Underlying amount: 697,650
Exercise price
Footnotes: F1, F3, F4

SCTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,131,344
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Jul 2026
Ownership: By AH Bio Fund III, L.P.
Underlying class: Common Stock
Underlying amount: 697,650
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

Footnote F2

The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

Footnote F3

The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.

Footnote F4

(Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.